Compare McKesson Corporation (MCK) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? McKesson Corporation trades at $825.15 (market cap $97.35B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.67. The key difference: McKesson Corporation pays a 0.39% dividend while Roundhill S&P 500 0DTE Covered Call Strategy ETF pays none, and McKesson Corporation is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MCK | XDTE | |
|---|---|---|
Market Cap | $97.35B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $995.69 | $44.76 |
52-Week Low | $659.01 | $36.00 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
XDTE (Roundhill S&P 500 0DTE Covered Call Strategy ETF) trades at $38.44, down 0.1% with a bearish technical signal. The ETF generates income through daily options strategies but faces concerns about net asset value erosion despite high dividend yields. Recent news highlights the fund's 32% yield but questions its sustainability as the math may not hold up over time.
The outlook remains cautious due to structural risks in the covered call strategy potentially limiting upside during market rallies. While offering frequent distributions, investors face the risk of underperforming the underlying S&P 500 index during strong bull markets. The fund's viability depends on market volatility conditions favorable to options selling strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
